Announcements Trials
Browse Landscape

Phase

Phase 1/2 1Phase 1 1

Status

Recruiting 2

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Sarcoma 2Other hematologic neoplasm 2

Conditions

Leukemia, Myeloid, Acute 188Leukemia, Lymphocytic, Chronic, B-Cell 69Myelodysplastic Syndromes 47Recurrence 30Leukemia 30Precursor Cell Lymphoblastic Leukemia-Lymphoma 24Lymphoma, Mantle-Cell 20Leukemia, Myelomonocytic, Chronic 19Hematologic Neoplasms 14Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 13Lymphoma, Non-Hodgkin 13Lymphoma 13Leukemia, Biphenotypic, Acute 13Burkitt Lymphoma 13Lymphoma, B-Cell, Marginal Zone 12Multiple Myeloma 11Lymphoma, Large B-Cell, Diffuse 11Neoplasms 10Waldenstrom Macroglobulinemia 8Myeloproliferative Disorders 8Lymphoma, Follicular 8Lymphoma, B-Cell 7Neoplasm, Residual 6Leukemia, Myeloid 5Blastic Plasmacytoid Dendritic Cell Neoplasm 5Precursor B-Cell Lymphoblastic Leukemia-Lymphoma 4Leukemia, Myelogenous, Chronic, BCR-ABL Positive 4GATA2 Deficiency 4Leukemia, Monocytic, Acute 3Immunoglobulin Light-chain Amyloidosis 3

Interventions

Cytarabine 4venetoclax 2Mitoxantrone 2Daunorubicin 2Cladribine 2thymoglobulin 1quizartinib 1pegylated granulocyte colony-stimulating factor 1fludarabine phosphate 1fludarabine 1blinatumomab 1Transplantation 1Thiotepa 1Tacrolimus 1Sorafenib 1Sirolimus 1Rituximab 1Razoxane 1Mesna 1Melphalan 1Leyk 1Idarubicin 1Granulocyte Colony-Stimulating Factor 1Gemtuzumab 1Filgrastim 1Etoposide 1Dexrazoxane 1Cyclophosphamide 1Bortezomib 1Azacitidine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Sarcoma, Myeloid × venetoclax × 1 year × Clear all
NCT04797767 2026-04-17

Venetoclax and CLAG-M for the Treatment of Acute Myeloid Leukemia and High-Grade Myeloid Neoplasms

University of Washington

Phase 1/2 Recruiting
62 enrolled
Other hematologic neoplasmSarcoma

Leukemia, Biphenotypic, Acute, Leukemia, Myeloid, Acute, Sarcoma, Myeloid

NCT05735184 2026-03-13

A Study to Investigate the Safety and Tolerability of Ziftomenib in Combination With Venetoclax/Azacitidine, Venetoclax, 7+3, or 7+3+Quizartinib in Patients With AML

Kura Oncology, Inc.

Phase 1 Recruiting
420 enrolled
Other hematologic neoplasmSarcoma

Leukemia, Leukemia, Myeloid, Acute, Hematologic Neoplasms, Sarcoma, Myeloid

Data powered by HemOnc (CC BY 4.0) Colophon âš¡